Because the 2 antifibrotics in use — pirfenidone and nintedanib — have differing mechanisms of action, when one is ineffective the other may provide benefit, thus improving survival.
Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
The understanding of the role of specific molecular mechanisms causing pulmonary hypertension in people with pulmonary fibrosis is growing but still in its infancy.
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.
Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.
Several patients were treated for idiopathic pulmonary fibrosis were identified as dental personnel.
Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.
Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.
Depression and anxiety may affect quality of life for patients with idiopathic pulmonary fibrosis.
